|
GLUE
|
Monte Rosa Therapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
GBIO
|
Generation Bio Co.
|
0.03%
|
US
|
NASDAQ
|
|
CNCE
|
Concert Pharmaceuticals, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
CCCC
|
C4 Therapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
BCAB
|
BioAtla, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ATAI
|
ATAI Life Sciences N.V.
|
0.03%
|
US
|
NASDAQ
|
|
ALPN
|
Alpine Immune Sciences, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ADAP
|
Adaptimmune Therapeutics plc
|
0.03%
|
US
|
NASDAQ
|
|
ACET
|
Adicet Bio, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
URGN
|
UroGen Pharma Ltd.
|
0.02%
|
US
|
NASDAQ
|
|
SELB
|
Selecta Biosciences, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
PRLD
|
Prelude Therapeutics Incorporated
|
0.02%
|
US
|
NASDAQ
|
|
OPTN
|
OptiNose, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
OMER
|
Omeros Corporation
|
0.02%
|
US
|
NASDAQ
|
|
NKTX
|
Nkarta, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
MRNS
|
Marinus Pharmaceuticals, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
KPTI
|
Karyopharm Therapeutics Inc.
|
0.02%
|
US
|
NASDAQ
|
|
HUMA
|
Humacyte, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
GRNA
|
GreenLight Biosciences Holdings, PBC
|
0.02%
|
US
|
NASDAQ
|